Oncolytics Biotech Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Operating Activities | ||
| Net Income | $-28.8M | $-22.8M |
| Depreciation & Amortization | — | — |
| Depreciation | $70.0K | $87.0K |
| Amortization | — | — |
| Stock-Based Compensation | $3.1M | $2.0M |
| Net Cash from Operating Activities | $-20.1M | $-19.9M |
| Investing Activities | ||
| Capital Expenditures | $6.0K | $174.0K |
| Business Acquisitions | — | — |
| Net Cash from Investing Activities | $-6.0K | $-174.0K |
| Financing Activities | ||
| Dividends Paid | — | — |
| Stock Repurchases | — | — |
| Net Cash from Financing Activities | $14.1M | $5.0M |
| Net Change in Cash | $-5.9M | $-15.3M |
| Free Cash Flow | $-20.1M | $-20.1M |